Walvax Biotechnology Co., Ltd. (300142)

Overview

Walvax Biotechnology Co., Ltd. is a prominent entity in China's biotechnology sector, focusing on researching, developing, producing, and marketing an array of vaccines. Founded in 2001 and based in Kunming, China, Walvax has carved a niche for itself in the healthcare industry by providing innovative vaccination solutions to combat various infectious diseases. With a strong commitment to enhancing public health, the company has made significant strides in offering immunization against COVID-19, streptococcus pneumoniae infections, cervical cancers, and more, through its diverse vaccine portfolio.

Products and Services

• SARS-CoV-2 mRNA Vaccine
  

  An mRNA vaccine designed to prevent COVID-19 in individuals aged 18 years and older, showcasing the company's innovation in tackling the global pandemic.

• 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
  

  Intended for infants and children from 6 weeks through 5 years of age, this vaccine targets invasive diseases caused by streptococcus pneumoniae, helping to safeguard against serious infections.

• Recombinant Human Papillomavirus Bivalent Vaccine
  

  This vaccine is pivotal in the prevention of cervical cancers and precancerous lesions caused by human papillomavirus, emphasizing Walvax's focus on cancer prevention.

• 23-valent Pneumococcal Polysaccharide Vaccine
  

  Designed for individuals aged 2 years and older, this vaccine provides broad coverage against pneumococcal diseases, highlighting its utility in preventing serious pneumococcal infections.

• ACYW135 Meningococcal Polysaccharide Vaccine
  

  Offers prevention against invasive meningococcal diseases for adults and children over 2 years of age caused by the bacterium Neisseria meningitidis, underscoring its significance in protecting against meningitis.

• Group A and C Meningococcal Polysaccharide Vaccine
  

  Targets disease prevention caused by Neisseria meningitidis serogroups A and C, available for adults and children over the age of 2 years, aiming to combat meningococcal diseases.

• Group A and Group C Meningococcal Conjugate Vaccine
  

  Provides immunity against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children aged 3 months through 5 years, enhancing disease prevention in young children.

• Haemophilus Influenzae Type b Conjugate Vaccine (Hib Vaccine)
  

  This vaccine is crucial for preventing invasive infections such as meningitis in children aged 2 months through 5 years, caused by Haemophilus influenzae type b.

• Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine (DTaP)
  

  Offers protection against diphtheria, tetanus, and pertussis for infants and children 3 months through 6 years of age, representing Walvax Biotechnology's commitment to combating childhood diseases.